Back to Journals » Cancer Management and Research » Volume 10

Total lymphocyte count, neutrophil–lymphocyte ratio, and platelet–lymphocyte ratio as prognostic factors in advanced non–small cell lung cancer with chemoradiotherapy

Authors Song X, Chen D, Yuan M, Wang H, Wang Z

Received 24 September 2018

Accepted for publication 8 November 2018

Published 5 December 2018 Volume 2018:10 Pages 6677—6683


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Ahmet Emre Eskazan

Xinyu Song,1,2,* Dawei Chen,3,* Ma Yuan,4 Haiyong Wang,1 Zhehai Wang1

1Department of Medical Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, China; 2School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong, China; 3Department of Radiation Oncology, Shandong Cancer Hospital affiliated to Shandong University, Jinan, Shandong, China; 4Department of Medical Oncology, Weihai Central Hospital, Weihai, Shandong, China

*These authors contributed equally to this work

The objective of this study was to investigate the prognostic significance and the efficacy evaluation of total lymphocyte count (TLC), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) in advanced non–small cell lung cancer (NSCLC) patients treated with chemoradiotherapy.
Patients and methods: A total of 389 advanced NSCLC patients who received chemoradiotherapy from 2011 to 2016 were enrolled in this retrospective study. TLC, NLR, and PLR were analyzed with overall survival (OS). Survival data were identified with the Kaplan–Meier method and optimal cutoff values with receiver operating characteristic curves.
Results: The median OS for all patients was 18.37 months. Pretreatment and median baseline TLC was 2.47×103/μL (±0.78); NLR, 3.15 (±3.96); and PLR, 143.82 (±91.77); corresponding cutoffs were 2.4, 3.4, and 136.1. Higher TLC was associated with superior median OS (21.78 vs 15.66 months, P<0.001), and higher NLR and PLR with worse median OS (NLR: 14.13 vs 23.8 months, P<0.001; PLR: 15.49 vs 22.04 months, P<0.001).
Conclusion: The lymphopenia indicators (TLC, NLR, and PLR) were significant prognostic indicators of survival in advanced NSCLC patients treated with chemoradiotherapy.

Keywords: TLC, NLR, PLR, advanced NSCLC, chemoradiotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]